Preoperative and postoperative prognostic factors of patients with stage II/III lower rectal cancer without neoadjuvant therapy in the clinical trial (JCOG0212)
Authors:
- Masayuki OhueMOMasayuki Ohue
- Shin FujitaSFShin Fujita
- Yukihide KanemitsuYKYukihide Kanemitsu
- Tetsuya HamaguchiTHTetsuya Hamaguchi
- Shunsuke TsukamotoSTShunsuke Tsukamoto
- Shingo NouraSNShingo Noura
- Masayoshi YasuiMYMasayoshi Yasui
- Masaaki ItohMIMasaaki Itoh
- Akio ShiomiASAkio Shiomi
- Koji KomoriKKKoji Komori
- Jun WatanabeJWJun Watanabe
Open Access
- 2 December 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 52 (2) , 114-121
Abstract
The JCOG0212 trial was a randomized controlled trial comparing mesorectal excision alone to mesorectal excision with lateral lymph node dissection for stage II/III lower rectal cancer patients without clinical lateral lymph node enlargement. This study aimed to identify clinicopathological prognostic factors for relapse-free survival and overall survival of lower rectal cancer in the trial. Prospective data were selected from 663 patients with complete data. Uni and multivariable Cox regression model was applied to evaluate the preoperative and the combined preoperative and postoperative factors, respectively. Preoperative factors included age, sex, performance status, clinical T, clinical N and operative procedures. Postoperative factors included histological grade, pathological T, number of metastatic lymph nodes and number of dissected lymph nodes. No patient received neoadjuvant treatment. Regarding preoperative factors, multivariable analysis revealed that performance status 1 (vs. 0: HR 2.079, P = 0.0041) and cT4a (vs. cT2–3: HR 2.721, P = 0.0002) were independent risk factors for relapse-free survival, and those for overall survival were male (vs. female: HR 1.660, P = 0.0228) and cT4a (vs. cT2–3: HR 2.486, P = 0.0473). The only independent preoperative risk factor common for relapse-free survival and overall survival was cT4a. Taking preoperative and postoperative factors together, the number of metastatic lymph nodes was the only independent risk factor common for relapse-free survival and overall survival. Clinical stage II/III lower rectal cancer patients with cT4a should be a target of therapeutic development of neoadjuvant therapy. Postoperatively, intensive chemotherapy should be investigated for patients with more metastatic lymph nodes.Keywords
Funding Information
- National Cancer Center Research and Development Funds (23-A-16, 23-A-19, 26-A-4, 29-A-3, 2020-J-3)
- Grants-in-Aid for Cancer Research (14S-4, 17S-3, 17S-5, 20S-3, 20S-6)
This publication has 17 references indexed in Scilit:
- Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification ModelAnnals of Surgery, 2016
- Pathologic stage following preoperative chemoradiotherapy underestimates the risk of developing distant metastasis in rectal cancer: A comparison to staging without preoperative chemoradiotherapyJournal of Surgical Oncology, 2016
- Tailored rectal cancer treatment – a time for implementing contemporary prognostic factors?Colorectal Disease, 2013
- Results of a Japanese Nationwide Multi-Institutional Study on Lateral Pelvic Lymph Node Metastasis in Low Rectal CancerAnnals of Surgery, 2012
- Prediction of lateral pelvic node involvement in low rectal cancer by conventional computed tomographyBritish Journal of Surgery, 2007
- Indication and Benefit of Pelvic Sidewall Dissection for Rectal CancerDiseases of the Colon & Rectum, 2006
- Preoperative evaluation of pelvic lateral lymph node of patients with lower rectal cancer: comparison study of MR imaging and CT in 53 patientsLangenbeck's Archives of Surgery, 2006
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerNew England Journal of Medicine, 2004
- Prognostic significance of radial margins of clearance in rectal cancerBritish Journal of Surgery, 1996
- RECURRENCE AND SURVIVAL AFTER TOTAL MESORECTAL EXCISION FOR RECTAL CANCERThe Lancet, 1986